Mission to ZERO Aims to Reset National Benchmark

Magnolia launches nationwide initiative to raise awareness of patient safety risks caused by false-positive diagnostic results for sepsis. The goal is to drive change by reducing the national blood culture contamination benchmark, while partnering with hospitals in their mission to eliminate blood culture contamination and false positive CLABSI reporting.

Newsweek Selects Steripath as a 2020 Best Product in Infection Prevention

The Best Health Care series by Newsweek and The Leapfrog Group highlights the nation's most promising products and technologies to help patients and healthcare workers avoid infection.

Introducing Steripath Gen2 with Integrated Syringe

The trusted solution for reducing blood culture contamination is now optimized for ‘hard stick’ patients and syringe collection protocols as the only diversion device with a preassembled, integrated syringe configuration.

Steripath Gen2 Products Receive FDA 510K Clearance with Exclusive Indication

The Steripath Gen2 product family are now the only FDA cleared devices indicated to reduce blood culture contamination when contaminants are present, compared to standard method controls without diversion.

Featured Videos

Learn More About Steripath

The Problem with False Positives

False-positive blood culture results can have meaningful downstream consequences. Learn about the impact.

Read More >
The Benefits of Steripath

See how you can benefit from reducing blood culture contamination at your hospital.

Read More >
Backed by Evidence

Discover Steripath's independent clinical study results for yourself.

Read More >
About Us

Discover Magnolia Medical's company history and current leadership

Read More >
Careers

Think you have what it takes to join Team Magnolia?

See Openings
Patents

Explore our vast portfolio of industry-leading, medical device innovation

Read More >